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Background: Coronary artery bypass graft surgery is the standard treatment of unprotected
left main coronary stenosis (ULMCA). However, in the real world scenario, many of these
patients are unﬁt for CABG or prefer angioplasty as an alternative when offered the choice.
Methods: A total of 86 clinically stable patients with ULMCA stenosis who were unﬁt or
unwilling for CABG underwent PCI with DES at two tertiary care centers in Kolkata. Patients
were followed up prospectively for a median of 34.6 months for major adverse cardiovascular
events. Angiographic follow-up was done after 1 year of index procedure or earlier, if indicated.
Results: Fifty-ﬁve patients (64%) had distal left main stenosis. Two-stent technique was used
in 19 patients (22%) and single-stent technique in 36 patients (42%) with distal left main
lesion. Thirteen patients (15.1%) had left ventricular ejection fraction (LVEF) of ≤45%. There
was no in-hospital death, MI, or stent thrombosis. During follow-up, major adverse cardiac
event (MACE) occurred in 9 patients (10.5%). Our study revealed signiﬁcantly greater MACE in
patients with distal left main lesion with LVEF ≤45% (50% vs 6.38%, p = 0.0002), high SYNTAX
score (36.36% vs 6.82%, p = 0.008), and diabetes (17.95% vs 0.00%, p = 0.07). Overall, also
patients with Diabetes, LVEF ≤ 45%, and SYNTAX score >32 had signiﬁcantly higher MACE.
Use of IC Stent, IVUS, or procedural strategy in distal lesion did not affect MACE.
Conclusion: In selective patients with low-intermediate SYNTAX score and without diabetes
and LV dysfunction, ULMCA PCI with DES is feasible.
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Signiﬁcant, unprotected left main coronary stenosis (ULMCA)
is a life threatening condition. It is found in 3–10% of the
patients undergoing coronary angiogram.1,2 Treated medical-
ly, this condition has unacceptably high 1-year mortality of
21%3 and 3-year mortality of 30–40%.4–7 Coronary artery bypass
graft surgery has shown improved long-term survival in
several trials,4–7 and currently, the standard of care for ULMCA
stenosis.8 PCI has long been tried as an alternative option in
treatment of coronary artery disease. PCI with bare metal
stents (BMS) were found to have low-procedural complications
but they had unacceptably higher rate of repeat revasculari-
zation rate.9–12 Since the advent of drug eluting stents (DES) in
2002, with the promise of vastly reduced rate of restenosis,
there has been a resurgence of interest of ULMCA stenting.
Several registries from different parts of the world have shown
comparable short-term outcomes in terms of death or MI that
rivals those of CABG.13–19 Guidelines support PCI in patients
with ULMCA stenosis who are not suitable for CABG.8 Here we
present our experience in ULMCA PCI from two tertiary care
hospitals in Kolkata using DES.
2. Methods
Study objective. Primary study objective was to assess major
adverse cardiac events (MACE), including all cause mortality,
MI, and TVR. Secondary objective was stent thrombosis (ST).
Patient population. From October 2008 to February 2014,
patients with de novo ULMCA stenosis, treated with new DES
implantation at two centers (AMRI Hospital, Salt Lake and
Fortis Hospitals, Anandapur, Kolkata) by a single group of
interventional cardiologists, were included in our registry.
Patients presenting with STEMI were excluded. Patients with
NSTE-ACS or unstable angina were medically stabilised before
PCI. SYNTAX score was calculated for all patients. As ULMCA
disease is still a Class I indication for surgery in the current
guidelines, patients were enrolled after proper counseling by
interventional cardiologists, cardiac surgeons, and internists
(Heart Team since 2012) in situations like (a) advanced age,
(b) critical co-morbidities, (c) patient unwilling for CABG,
(d) Estimated short life expectancy (known malignancy) and
(e) post-CABG with occlusion of left internal mammary artery/
RSVG graft to LAD & LCx making the situation as unprotected
LMCA disease.
Medications and PCI. Each patient was preloaded with
clopidogrel (600 mg) and used 75 mg in combination with
aspirin 150 mg daily for 12 months. Aspirin 75 mg was
continued indeﬁnitely thereafter. All the procedures were
performed via transfemoral route. Intraprocedural unfractio-
nated heparin (with a goal activated clotting time of ≥300 s)
was administered during the procedure.
Coronary angioplasty and stent implantation, including
bifurcation strategy in the case of distal disease, were
performed according to the operator's preference, with the
aim of complete coverage of the diseased segment. The use of
prophylactic intra-aortic balloon pump (IABP), periprocedural
glycoprotein IIb/IIIa inhibitors, atherectomy devices, IVUSguidance (Boston Scientiﬁc), and Enhanced Stent Visualisation
(ESV) system (Siemens IC Stent) was at operator discretion.
Stents used in our patients include Cypher (Cordis) Sirolimus
eluting stent, Taxus Liberte (Boston Scientiﬁc) Paclitaxel
eluting stent, Promus Element/Promus Element Plus/Synergy
(Boston Scientiﬁc) or Xience V/Xience Prime (Abbot Vascular)
Everolimus eluting stent, and Endeavour Sprint/Endeavour
Resolute/Integrity Resolute (Medtronic) Zotarolimus eluting
stent.
All patients gave informed written consent for the
procedure and subsequent data collection during follow-up.
The study was approved by ethical committees of the
respective institutes.
Follow-up. All patients were followed up during hospital
stay, after discharge at 1 month, 6 months, 1 year and then
yearly by clinic visit or telephonic contact. Coronary angio-
gram was planned in all patients after 1 year of index
procedure or earlier if indicated. Follow up was recorded till
February 2015.
Deﬁnitions. Death was classiﬁed as either cardiac or non-
cardiac according to the Academic Research Consortium (ARC)
deﬁnitions.20
Periprocedural non-Q wave MI was deﬁned as elevation of the
serum creatinine kinase isoenzyme MB (CK-MB) to 3-times the
upper limit of normal, in the absence of new pathological Q-
waves. Q-wave MI was deﬁned as the development of new
pathological Q-waves in 2 or more contiguous leads, with or
without CK-MB elevation above normal. Spontaneous MI was
deﬁned as the occurrence after hospital discharge of any value
of troponin and/or CK-MB greater than the upper limit of normal
if associated with clinical and/or electrocardiographic changes.
TVR was deﬁned as any repeat PCI or surgical bypass of any
segment of the target vessel, deﬁned as the entire major
coronary vessel proximal and distal to the target lesion,
including upstream and downstream branches and the target
lesion itself.
TLR was deﬁned as any repeat PCI of the target lesion, or
bypass surgery of the target vessel performed for restenosis.
The target lesion (restenosis) was deﬁned as the treated segment
from 5 mm proximal to 5 mm distal to the stent.
Deﬁnite, probable, and possible ST were determined
according to the ARC deﬁnitions.20
Statistical analysis. Data are presented in percentages and
mean  S.D. Categorical variables are presented as percen-
tages and compared with chi-square testing. Statistical
signiﬁcance was established at a = 0.05 level. Kaplan–Meier
survival curves were obtained along with 95% conﬁdence
limits for survival curves in overall population and analysed
with log rank test method. Cox's proportional hazard model
was used to determine hazard ratios (using Efron approxima-
tion). Analysis was performed using Statistical software R
(R Foundation for Statistical Computing, version 2.6.2).
3. Results
A total of 86 patients with de novo ULMCA stenosis treated
with DES were included in the study. Baseline patient
characteristics and angiographic characteristics are shown
in Tables 1 and 2.
Table 2 – Angiographic characteristics in patients with
ULMCA stenosis undergoing PCI with DES.
Angiographic characteristics No. of patients
(n = 86) (%)
Isolated LMCA disease 59 (68.6%)
LMCA + 1-vessel disease (LAD/LCx/RCA) 27 (31.4%)
LMCA + right coronary total occlusion 2 (2.33%)
Ostial or shaft lesion 31 (36.05%)
Distal lesion 55 (63.95%)
Calciﬁed distal lesions 18 (20.93%)
Distal disease and bifurcation type (n = 55)
Medina 1, 1, 1 12 (21.82%)
Medina 0,1,1 7 (12.73%)
Medina 1, 0, 1 6 (10.91%)
Medina 1, 1, 0 30 (54.54%)
Syntax score (23.44 W 8.64)
0–22 54 (62.79%)
23–32 20 (23.26%)
≥33 12 (13.95%)
Table 1 – Baseline clinical characteristics in patients with
ULMCA stenosis undergoing PCI with DES.
Population characteristics No. of patients (n = 86)
(%)/Mean  SD
Male 65 (75.58%)
Female 21 (24.42%)
Age (Years) (Mean) 59.43  11.29
Presenting features
Stable angina 14 (16.28%)
Unstable angina 49 (56.98%)
NSTEMI 20 (23.26%)
Post STEMI angina (<2 weeks after
thrombolysis)
1 (1.16%)
Post CABG LIMA/RSVG occlusion 2 (2.32%)
LV ejection fraction (Mean) 54.02%  7.33%
Co-morbidities
Hypertension (HTN) 75 (87.21%)
Diabetes mellitus (DM) 58 (67.44%)
Smoking 38 (44.19%)
CRF 3 (3.49%)
Hypertension & diabetes mellitus 51 (59.30%)
Hypertension, diabetes mellitus
& smoking
15 (17.44%)
Hypertension, diabetes mellitus,
smoking & CRF
1(1.16%)
LV ejection fraction ≤45% 13 (15.12%)
Table 3 – Procedural characteristics in patients with
ULMCA stenosis undergoing PCI with DES.
Procedure characteristics No of patients (%)
Use of IABP 2 (2.33%)
Use of GP2b3a 15 (17.44%)
Type of DES
Paclitaxel eluting stent 19 (22.1%)
Sirolimus eluting stent 30 (34.88%)
Everolimus eluting stent 25 (29.07%)
Zotarolimus eluting stent 12 (13.95%)
Distal lesion
1 Stent (Provisional Stenting strategy) 36/55 (64.45%)a
2 Stents strategy 19/55 (34.55%)
Distal lesion with 2 Stents
Simultaneous Kissing stenting 7/19 (36.84%)
Double Kissing Crush 12/19 (63.16%)
Use of IC stent 66 (76.74%)
Use of IVUS 18 (20.93%)
Use of Rotablation 18 (20.93%)
a Two patients required second stent (T and proprusion).
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male, and 58 (67.44%) were diabetic. Among the total of
86 patients, 14 patients had stable angina, 49 had unstable
angina, 20 patients had NSTEMI, 1 patient had post-STEMI
angina after thrombolysis (<2 weeks), and 2 patients had post-
CABG occlusion of LIMA-RIMA to LAD & LCx. Thirteen (15.12%)
patients had left ventricular ejection fraction (LVEF) ≤45%.
Fifty-nine patients (68%) had isolated left main coronary
disease. Fifty-ﬁve patients (63.95%) had distal LMCA lesion
Medina 1,1,1 bifurcation lesion was present in 19 patients
(34.55%). Mean SYNTAX score of the study population was
23.44  8.64 with majority of patients (62.79%) having low
SYNTAX score.Procedural characteristics are shown in Table 3. Among the
55 patients with distal lesions, two-stent technique was
employed in 19 patients (34.55%). Among those, simultaneous
kissing stent technique was applied in 7 (36.84%) and double
kissing crush (DK Crush) technique was applied in 12 (63.16%).
Rest of the patients were treated by provisional stenting
strategy (65.45%). Among them, 2 patients required a second
stent, which was implanted by T and protrusion technique.
Procedural success was achieved in all patients. There were
no in-hospital deaths or periprocedural MI. Minimum follow-
up period was 1 year, and maximum follow-up period was
6.5 years. During follow-up 9 patients (8.24%) had MACE,
including 3 deaths (3.49%). Two patients had MI due to ST.
During angiographic follow-up, 4 patients (4.65%) had in-stent
restenosis.
Table 4 shows MACE in different subgroups. Age or sex did
not affect MACE in our cohort. As a whole, patients with distal
lesion were not found to have higher incidence of MACE
compared to those with non-distal lesion. However, patients
with high SYNTAX score (>32) had a signiﬁcantly higher MACE
compared to those with low to intermediate (≤32) SYNTAX
score (p = 0.005). Patients with distal LMCA lesion with high
SYNTAX score had signiﬁcantly higher MACE compared to
those with distal LMCA lesion and low-intermediate SYNTAX
score (6.82% vs 36.36%, p = 0.008). Also, incidence of MACE in
patients with LVEF ≤ 45% (30.77%) is signiﬁcantly higher than
patients with LVEF >45% (6.85%), with p value 0.007 (Fig. 1).
Also, in patients with distal ULMCA lesion, those with LVEF
≤45% had signiﬁcantly greater incidence of MACE than those
with LVEF > 45% (50% vs 6.38%, HR = 10.04, p = 0.0002). More-
over, patients with distal lesion and LVEF ≤45% had higher
MACE compared to patients with non-distal lesion and LVEF
≤45% (50% vs 0%, p = 0.07), though it did not reach statistical
signiﬁcance.
Patients with distal lesion and diabetes had higher but
statistically non-signiﬁcant MACE compared to those with
distal lesion and no diabetes (17.95% vs 0%, p = 0.08). But as a
Table 4 – Incidence of MACE in different subgroups of the study population.
Characteristics PTCA MACE % of MACE HR log rank p value
Male 65 5 7.69% HR = 2.69
95% CI (0.722, 10.0)
0.125
Female 21 4 19.05%
Age ≤60 years 45 3 6.67% HR = 2.26
95% CI (0.566, 9.04)
0.236
Age >60 years 41 6 14.63%
Non-calciﬁed lesion
(Non-calciﬁed distal lesion
/Non-distal lesion)
68 6 8.82% HR = 1.91
95% CI (0.477, 7.62)
0.354
Calciﬁed distal lesion 18 3 16.67%
No distal lesion 31 2 6.45% HR = 2.02
95% CI (0.42, 9.72)
0.371
Distal lesion 55 7 12.73%
Diabetes 58 0 0.00% – 0.0306*
No diabetes 28 9 32.14%
LV ejection fraction >45% 73 5 6.85% HR = 5.07
95% CI (1.36, 18.9)
0.00713*
LV ejection fraction ≤45% 13 4 30.77%
Syntax score ≤32 74 5 6.76% HR = 5.36
95% CI (1.44, 20)
0.00511*
Syntax score >32 12 4 33.33%
No distal lesion & LV ejection fraction ≤45% 5 0 0.00% – 0.0758
Distal lesion & LV ejection fraction ≤45% 8 4 50.00%
No distal lesion & LV ejection fraction >45% 26 2 7.69% HR = 0.8200
95% CI (0.137, 4.908)
0.8276
Distal lesion & LV ejection fraction >45% 47 3 6.38%
No distal lesion & diabetes mellitus 19 2 10.53% HR = 1.75
95% CI (0.364, 8.43)
0.479
Distal lesion & diabetes mellitus 39 7 17.95%
PTCA with IC Stent (ESV) 66 6 9.09% HR = 1.8080
95% CI (0.452, 7.231)
0.396
PTCA without IC Stent 20 3 15.00%
PTCA with IVUS 18 1 5.55% HR = 2.24
95% CI (0.281, 17.9)
0.434
PTCA without IVUS (with/without IC Stent) 68 8 11.76%
* Statistically significant at p < 0.05.
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(p = 0.03).
Incidence of MACE with distal lesion treated by different
techniques did not vary signiﬁcantly. Incidence of MACE did
not differ signiﬁcantly in patients with distal ULMCA lesion
treated with single- or double-stent strategy ( p = 0.19) (Table 5).
IC Stent or IVUS use was not associated with signiﬁcant
difference in incidence of MACE in patients with non-distal/
distal lesion in this study cohort (Tables 5 and 6).Fig. 1 – Kaplan–Meier's Survival curves for two groups of
LMPCI population – LV ejection fraction >45% (upper curve)
and LV ejection fraction ≤45% (lower curve) log rank p value
0.007.All MACE found in our study occurred within 1 year of index
procedure. Kaplan–Meier analysis of survival free of MACE was
found to be 89.5% in these patients at 1-year follow-up (Fig. 2).
4. Discussion
The study was conducted with the purpose of analyzing the
ULMCA PCI patients in a real world scenario. The longest
available follow-up in our study is 6.3 years and a median
follow-up of 34.6 months. During hospital stay, no patient had
MACE. During follow up, period MACE occurred in 10.5%
patients. The major ﬁndings of this study are: (1) PCI of
patients with ULMCA disease with DES is a viable option in
view of a promising survival rate; (2) age, sex, or type of
stenting technique did not affect MACE; (3) in patients with
diabetes, compromised LV function (EF ≤45%) and high
SYNTAX score MACE rate are high; (4) patients with distal
ULMCA lesion with LV dysfunction (EF ≤45%) had signiﬁcantly
higher MACE; (5) patients with distal ULMCA lesion and high
SYNTAX score had signiﬁcantly higher MACE and (6) Use of
IVUS and ESV (IC Stent) technology is not associated with
lower incidence of MACE.
Several trials have presented outcomes of ULMCA PCI using
DES over the recent years.21–24 Results reported in these
studies vary widely due to variation in patient selection and
procedural technique. Most of these studies have shown that
lesions involving left main ostium and shaft have better
outcomes than distal left main lesions in terms of MACE.
Signiﬁcantly higher MACE was demonstrated in emergent or
urgent ULMCA PCI, whereas favorable short- and long-term
Table 5 – Incidence of MACE in patients with distal LMCA lesion.
Characteristics PTCA MACE % of MACE HR log rank p value
LV ejection fraction >45% 47 3 6.38% HR = 10.0409
95% CI (2.234, 45.14)
0.000209*
LV ejection fraction ≤45% 8 4 50.00%
Syntax score ≤32 44 3 6.82% HR = 5.93
95% CI (1.32, 26.6)
0.0083*
Syntax score >32 11 4 36.36%
1 Stent PTCA 36 3 8.33% HR = 2.6048
95% CI (0.5825, 11.65)
0.1933
2 Stents PTCA 19 4 21.05%
2 Stents SKS PTCA 7 0 0.00% - 0.101
2 Stents DKS PTCA 12 4 33.33%%
No diabetes mellitus 16 0 0.00% - 0.07734
Diabetes mellitus 39 7 17.95%
PTCA with IC Stent (ESV) 43 4 9.30% HR = 3.2232
95% CI (0.7202, 14.43)
0.1054
PTCA without IC Stent 12 3 25.00%
PTCA with IVUS 13 1 7.69% HR = 1.989
95% CI (0.2394, 16.52)
0.5163
PTCA without IVUS (with/without IC Stent) 42 6 14.29%
* Statistically significant at p < 0.05.
Table 6 – Incidence of MACE in patients with No distal LMCA lesion.
Characteristics PTCA MACE % of MACE log rank p value
LV ejection fraction > 45% 26 2 7.69% 0.5311
LV ejection fraction ≤ 45% 5 0 0.00%
PTCA with IC Stent 8 0 0.00% 0.399
PTCA without IC Stent 23 2 8.70%
PTCA with IVUS 5 0 0.00% 0.5311
PTCA without IVUS (with/without IC Stent) 26 2 7.69%
Syntax score ≤32 30 2 6.67% 0.795
Syntax score >32 1 0 0.00%
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study, more than half of the patients had distal LM involve-
ment, with Medina classiﬁcation 1.1.0 and 1.1.1 being the most
prevalent disease patterns. This ﬁnding is consistent with data
from previous trials and registries, including the SYNTAX
trial.28
The SYNTAX trial was a randomized controlled trial
that evaluated the efﬁcacy and safety of PCI using PES forFig. 2 – MACE free survival of overall population with
ULMCA PCI with data showing population at risk.1800 patients with three-vessel and/or left main disease. In the
left main subgroup analysis for 348 patients undergoing CABG
and 357 receiving PCI, PCI demonstrated equivalent 1-year
clinical outcomes of MACCE, including death, MI, stroke, and
repeat revascularization compared with CABG. The SYNTAX
study group created the SYNTAX score to classify angiographic
complexity and predict outcomes of patients who are treated
with revascularization. The score takes into account, anatomic
complexities including calciﬁcation, bifurcation lesions, total
occlusion, thrombus, and long lesions. In spite of some
limitations, such as absence of clinical proﬁles and wide
interobserver variation, the score is considered to be a useful
predictor for the extent of coronary disease and provides
important information for deciding the revascularization
strategy. In the SYNTAX study, the low (0–22; 26% vs 28.4%;
p = 0.6) and intermediate SYNTAX (23–32; 29.5% vs 29.7%;
p = 0.9) score groups had comparable 4-year incidences of
MACCE between PCI and CABG groups.18 However, in the high-
score group (≥33), PCI showed a higher incidence of MACCE
than CABG (42.6% vs 26.3%; p < 0.003).
Mean SYNTAX score observed in our cohort was lower than
that reported in the left main subset of PCI-treated patients of
the SYNTAX trial (23.44  8.64 vs 28.1  12.4). However,
patients with high SINTAX score had signiﬁcantly higher
MACE compared to those with low-intermediate SYNTAX
score. In our study, there was no signiﬁcant difference in MACE
between distal and non-distal lesions. But interestingly,
patients with distal lesion and high SYNTAX score had
signiﬁcantly higher MACE compared to those with distal
lesions with low-intermediate SYNTAX score (p = 0.008). On
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with high SYNTAX score did not have higher MACE compared
to patients with low-intermediate SYNTAX score and non-
distal lesions. A study by Kim et al. showed that the
angiographic SYNTAX score plays a partial role in predicting
long-term adverse events after PCI for ULMCA stenosis and
suggested that including clinical risks may improve the
predictive ability of the score.29
All the MACE observed in our study occurred within 1-year
follow-up. MACE observed in our study is lower than other
similar studies.30,31 The reason may be that highly selective
and mostly clinically stable patients were included in our
study. Distal LMCA bifurcation treated with multiple stents
was found to be associated with worse outcome.32–35 In our
study, 64.45% patients with distal LMCA stenosis were treated
by single stent strategy.
Mostly simultaneous kissing stenting (SKS) and Double
kissing crush (DKC) were the techniques selected for 2-stent
strategy. None of the techniques were found to be superior to
the other in terms of MACE. Simultaneous kissing stenting in
our study was done mostly in patients with Medina 0,1,1
lesions with <5 mm proximal overlap. Probably that may be
the reason that there was no restenosis in this group. Recent
studies show that if stenting is performed by experienced
operators, either single- or two-stent techniques for bifurca-
tion yielded a comparably feasible long-term outcome
compared to CABG, even for bifurcation ULMCA stenosis.36
In recent years, data have been published showing the role
of ESV technique in complex PCI.37–40 This technique is helpful
during stent placement and guides optimal stent expansion. It
involves the creation of an enhanced exposure image that
clearly outlines the geometry of the deployed stent from a
ﬁxed viewing direction. The enhancement is achieved by
employing a motion-compensation process and temporal
integration of the image sequence to increase contrast
visibility. IVUS is considered the gold standard for assessment
of stent malapposition. Improved procedural outcomes, such
as increased luminal diameter and reduced restenosis rates,
have been documented when using IVUS with PCI.41,42 ESV is
considered to be complimentary to IVUS. However, in our
study, use of IC Stent was not associated with better clinical
outcome in terms of MACE (p = 0.4). Use of IVUS was associated
with a lower MACE compared to no IVUS (5.55% vs 11.76%),
though it did not reach statistical signiﬁcance.
Studies have shown that low EF is an independent predictor
of mortality following LMCA PCI.30,43 Recently, developed
SYNTAX score II, which combines both the anatomical and
clinical factors to assess risk after PCI, has included LV EF as a
major clinical risk factor with great prognostic value.44 DELTA
registry,45 the multinational all-comer registry of ULMCA PCI
with DES has shown that SYNTAX score and LVEF are
predictors of primary endpoints.
In our study, left ventricular EF ≤45% was found to be
associated with signiﬁcantly higher MACE in the overall study
population. In patients with distal LMCA, lesion EF ≤45% was
also associated with signiﬁcantly higher MACE.
Diabetes has been shown to be associated with increased
MACE in ULMCA disease treated with DES.46 In our study also,
we found higher MACE in patients with diabetes compared to
those with no diabetes (p = 0.03).5. Study limitations
This study has several limitations. First, small sample size
prevents us to draw any ﬁrm conclusion regarding clinical
outcomes. This analysis is intended for descriptive purpose
only. Second, selection of clinically stable patients for elective
PCI prevents the ﬁndings to be extrapolated to patients with
STEMI or cardiogenic shock. There was no comparison with
CABG. Operator preference was used in each procedure
regarding use of ESV/IVUS, choice of technique, and stent
used to treat the lesion, which may lead to confounding.
Mostly, ﬁrst-generation stents were used in this study. We also
did not look at the risk scores of the study population. Despite
these limitations, this analysis provides a descriptive assess-
ment of outcomes of clinically stable patients with signiﬁcant
ULMCA lesion undergoing PCI with DES.
6. Conclusion
Elective PCI with DES is a viable option in selective patients
with ULMCA stenosis. Patients with high SYNTAX score, left
ventricular dysfunction with EF ≤45%, and diabetes are at
higher risk for developing MACE following ULMCA PCI. Role of
IVUS or Enhanced Stent Visualisation in clinical outcome
should be evaluated in a larger population.
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